




FIN VAL
RESEARCH & CONSULTANCY

THE Global INFOWAVE: YOUR WEEKLY PULSE

❖ Finance, Valuation & Fund Raising



Research Articles published this week

➤ **Global vs Indian ESOPs: What Investors Prefer**

Global ESOPs offer mature governance, tax benefits, and strong liquidity options. Indian ESOPs are rapidly evolving with SEBI clarity, rising buybacks, and growing investor confidence. Investors now prefer hybrid ESOP models blending India's agility with global standards for scalability, transparency, and improved valuation outcomes.

[Read More](#)

➤ **The Evolution of Valuation in Private Markets -What Every Founder & Investor Must Know**

Private market valuation is shifting to faster, data-driven, and future-focused models. AI, SaaS metrics, ESG premiums, scenario analysis, and token valuation now complement traditional methods. The emerging standard is a hybrid approach blending DCF, comparables, AI insights, and risk-adjusted scenarios for more accurate, transparent valuations.

[Read More](#)

❑ **Abbott dives into cancer diagnostics with \$23B buyout of Exact Sciences**

Abbott signed up to buy Exact Sciences, the maker of the Cologuard at-home screening test for colorectal cancer in addition to new blood-based tests for detecting multiple tumors in their early stages and spotting the recurrence of malignancies after treatment.

The additions of cancer screening and precision oncology to its diagnostics portfolio are slated to double the business’s total addressable market to more than **\$120 billion**—with Abbott estimating that about **20 million** people worldwide, including **2 million** in the U.S., receive a cancer diagnosis each year.



Brief on U.S.A Healthcare Market Size: Market size was valued at \$4 trillion in 2024 and is expected to reach around \$7.64 trillion by 2033 with a CAGR of 5.80% from 2025 to 2033.

Finval Analysis: Investors reward companies with differentiated technology, scalable diagnostics platforms, and strong clinical adoption pathways. Guardant and Exact Sciences benefit from this narrative, while Natera reflects a more cautious market sentiment.

In contrast, Abbott’s moderate multiple is consistent with its predictable earnings profile and diversified product portfolio, emphasizing stability over hypergrowth.

Company	Valuation (2025)	Revenue	Revenue Multiple
Abbott Lab	~\$220 B	~42 B	~5x
Exact Sciences	~\$21 B	~3 B	~7x
Guardant Health	~\$6.5 B	~\$564 M	~11x
Natera	~\$1.04B	~\$564 M	~1.05x

- ❑ **FNZ raises \$650 million growth equity (UK) — among largest fintech fundraises globally this week.**

FNZ, the global wealth-management platform, has secured US\$650 million in new equity funding from its institutional shareholders. This provides further financial strength to support its long-term business plan and its commitment to delivering enhanced outcomes for clients worldwide.

This new capital supports FNZ’s credit ratings and enables the company to deliver on its strategy to drive sustainable growth by investing in its technology, people and products, and delivering for its clients.



Brief on Global Wealth Management Market Size: The market is expected to grow from \$1.8 trillion in 2023 to \$2.5 trillion in 2028 at a rate of 7.03%. The market is then expected to grow at a CAGR of 6.94% from 2028 and reach \$3.5 trillion in 2033.

Finval Analysis: Among the three, FNZ is the fastest-scaling pure platform, Envestnet is the broadest advisor-focused ecosystem, and SEI is the most financially stable and diversified operator. The sector shows a clear trend toward platformization and recurring tech-driven revenues, with each player occupying a distinct but complementary strategic niche.

Company	Recent All Asset	Known Revenue /Valuation
FNZ	~\$2T	\$20B Valuation (2022)
Envestnet, Inc	~\$5.8T	~\$1.09B Recurring Revenue
SEI Inv.	~1.6T	~2.12B

□ **Metropolis raises \$500 million in Series D to expand AI-powered parking & urban-transaction infrastructure globally.**

Metropolise, a Los Angeles-based provider of parking lot technology, secured **\$1.6B** in financing, including a **\$1.1B** Term Loan B arranged by JP Morgan Chase Bank and a **\$500M** Series D round led by LionTree. The round values Metropolis at **\$5B**.

Metropolis supports over **\$5B** in annual transactions, serves **50M** customers and counts nearly **20M** members across its growing network. With this new capital, the company will accelerate its expansion in parking, retail, hospitality, fueling and mobility, and building an intelligent infrastructure layer that seamlessly connects people to the physical world.



Brief on Global Smart Parking Market Size: Market size was estimated at \$9.15B in 2024 and is predicted to increase to \$64.50B by 2034, expanding at a CAGR of 21.57% from 2025 to 2034.

Finval Analysis: The revenue disparity shows that the parking-tech industry is highly fragmented, with Metropolis positioned as a consolidator and other players operating in niche, city-specific or data-services verticals. This also indicates that the industry may be moving toward platform consolidation, connected-car integrations, and automation-led monetization rather than pure consumer parking apps.

Company	Recent Revenue or relevant metric
Metropolis	>\$5B Annual Transaction Volume
SpotHero	~\$46M
ParkMobile	~\$92M
Parkopedia	~\$65M

❑ **Wonderful secures \$100 million Series A to build enterprise-grade multilingual AI agents.**

Israeli AI agent startup Wonderful has raised \$100 million in a Series A round led by Index Ventures, with participation from Insight Partners, IVP, Bessemer, and Vine Ventures.

The round brings Wonderful's total funding to **\$134 million** just four months after the startup came out of stealth with a seed round and a promise to help enterprises deploy customer-facing AI agents across voice, chat, and email in every market and every language.



wonderful

Finval Insight

Brief on Asia – Pacific AI Market Size: Market is valued at \$66.38B in 2024 and is expected to grow at \$1.3T by 2033 at a CAGR of 39.93%.

Finval Analysis: The three companies represent different stages and strategies in the AI-voice ecosystem:

Wonderful → Fast-growing, product-heavy, early-stage disruptor,

PolyAI → Enterprise-focused, technically advanced, sticky margins,

SoundHound AI → Largest and most established, diversified but slower-moving

Company	Recent Revenue	Valuation	Revenue Multiple
Wonderful	\$10M	\$700M	~70x
PolyAI	\$50M	\$500M	~10x
Sound HoundAI	\$84M	~\$840M	~10x

❑ **Synchron raises \$200 million Series D to commercialize its brain-computer interface platform (Stentrode).**

Synchron develops brain-computer interface (BCI) technology, aiming to enable direct brain-to-computer communication for medical/neuro applications. The funding supports clinical development and global commercialization.

The large raise signals sustained investor conviction in frontier neurotech. If Synchron gets regulatory approvals and demonstrates clinical viability, it could lead in a nascent but high-value field (neurotech + MedTech convergence). Risk remains high — clinical & regulatory execution will be critical — but upside is potentially massive given unmet need.



Brief on Neurotechnology & Brain Computer Interface Market Size: Neurotechnology market will increase from \$15B in 2024 to \$53B by 2034, experiencing a CAGR of 13.23%.

As BCI market is on early stage but can be forecasted to grow to several tens of billions USD over next decade as neurotech adoption expands.

Finval Analysis: Synchron focuses on minimally invasive, commercially viable implantation, Neuralink pushes high-bandwidth neural data through fully implanted robotics, and Paradromics targets medical-grade, high-resolution neural signals. Together, they represent the accelerating race to translate BCI technology into real-world neurological therapies.

Company	Recent Revenue	Valuation	Revenue Multiple
Synchron	\$140M	~\$1B	~8x
Neuralink	\$220M	~\$9B	~40x
Paradromics	\$60M	~105M	~1.5x

Terminology

Brain – Computer Interface (BCI)

A Brain–Computer Interface (BCI) is a system that enables direct communication between the brain and external devices by translating neural activity into digital commands.

Types

- Non-invasive BCIs – Electroencephalography (EEG)(external sensors)
- Minimally-invasive BCIs – Endovascular or surface implants (e.g., Synchron)
- Invasive BCIs – Fully implanted electrodes for high-resolution neural data (e.g., Neuralink)

Advantages

- Enables direct control without physical movement
- High potential for restoring lost neurological functions
- Supports precision neuro-monitoring and personalized therapy
- Expands opportunities for robotics, prosthetics, and MedTech innovation

Disadvantages

- Invasive methods pose surgical and safety risks
- High cost, limited accessibility, and long regulatory pathways
- Data accuracy challenges in non-invasive systems
- Ethical, privacy, and long-term safety concerns remain

About US

Founded in 2011, we are a boutique consulting firm focused on providing world class financial consulting, valuations and corporate finance services.

Managed and advised by Registered Valuers with more than 70 years of cumulative experience and more than 200 valuation assignments.

Virtual CFO Solutions / Management Consulting

- Policies and Procedures
- Budget & MIS Reporting
- Long Term Financial Planning
- Work Capital Management
- Treasury Operations
- ESOP Advisory Services
- General Accounting & Book-keeping
- India Market Entry and Strategy Consulting

Transaction Advisory Services

- Business plan & Financial Modelling
- Fund Raising and M&A Support
- Due Diligence
- Valuation Service

Valuation Service

- Business Valuation
- Intangible Asset Valuations
- Startup Valuation
- Valuation as per IAS for Fair value of Financial Assets

THANK YOU

VALUATION@FINVALRESEARCH.IN

+91 98 112 13275

WWW.FINVALRESEARCH.IN